Additionally, exosome-based RNA therapeutics, such as KRAS-targeted siRNA, have shown promise in silencing oncogenes in pancreatic cancer, as demonstrated in Phase I trials [39]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.